Table 2.

Estimated pharmacokinetic parameters after administration of 1.0 mg kg⁻¹ vigabatrin to rats.

Formulation	0	1	2	3	4	5	6
Route of adm.	iv	PO	PO	PO	PO	PO	PO
Dietary component	None	None	Infant formula	Low fat infant formula	Pro/Trp	Sar	BCH
AUC0–∞ (h ng mL−1)	2421 ± 182	1747 ± 96	1751 ± 59	1781 ± 37	1770 ± 86	1763 ± 70	1839 ± 68
tmax (h)		0.25 [0.25; 0.33]	0.67 [0.67; 0.67]*	0.67 [0.58; 0.66]*	0.33 [0.33; 0.33]	0.67 [0.67; 0.75]*	0.33 [0.33; 0.33]
Cmax (ng mL−1)		1403 ± 124	965 ± 64*	984 ± 45*	1084 ± 75*	920 ± 31*	1215 ± 73
CL(mL h−1 kg−1)	426 ± 34	581 ± 30	574 ± 19	563 ± 12	571 ± 26	572 ± 23	548 ± 20
ke (h−1)	2.0 ± 0.2	0.7 ± 0.0	0.7 ± 0.0	0.7 ± 0.0	0.7 ± 0.1	0.7 ± 0.0	0.7 ± 0.1
Fabs (%)	100	72 ± 4	72 ± 2	74 ± 2	73 ± 4	73 ± 3	76 ± 3

C_max, AUC_0–∞, CL, k_e, and F_abs are expressed as mean ± SEM, t_max is expressed as the median [Q1; Q3] (25% and 75% percentile) from six rats.

^*Significant difference from oral administration of vigabatrin 1.0 mg kg⁻¹ (P < 0.05).